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Alcalá de Henares, Madrid, Spain
Correspondence should be addressed to Santiago Coca; s.coca@uah.es
Received 18 September 2019; Revised 25 November 2019; Accepted 11 January 2020; Published 9 March 2020
Guest Editor: Ludmila Grzybowska-Szatkowska
Copyright © 2020 Miguel A. Ortega et al. .is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Breast cancer is the cancer with the highest prevalence in women and is the number-one cause of cancer mortality worldwide. Cell
transduction is a fundamental process in the development and progression of cancer. Modifications in various cell signalling
pathways promote tumour cell proliferation, progression, and survival..e PI3K/Akt/mTOR pathway is an example of that, and it
is involved in growth, proliferation, survival, motility, metabolism, and immune response regulation. Activation of this pathway is
one of the main causes of cancer cell resistance to antitumour therapies..is makes PI3K/Akt/mTOR signalling a crucial object of
study for understanding the development and progression of this disease. .us, this pathway may have a role as a potential
therapeutic target, as well as prognostic and diagnostic value, in patients with breast cancer. Despite the existence of selective
PI3K/Akt/mTOR pathway inhibitors and current clinical trials, the cellular mechanisms are not yet known. .e present review
aims to understand the current state of this important disease and the paths that must be forged.
1. Introduction: Current State of the Disease
Breast cancer is the most prevalent cancer type in women as
well as the leading cause of cancer mortality in this pop-
ulation worldwide, with a peak incidence between 45 and 65
years of age [1]. Although it is not common, breast cancer
can also occur in men, with a frequency of 1 in 100 diag-
nosed cases, representing less than 1% of all cancers in
men [2].
Among the most important risk factors associated with
breast cancer are ageing, family history, nulliparity, hor-
monal factors, such as early menarche or late menopause,
and other factors related to lifestyle, such as alcohol con-
sumption, obesity, and physical inactivity [3, 4].
Breast cancer can be hereditary or sporadic. .e most
frequent mutations associated with hereditary cancer in-
clude those that affect DNA damage repair (DDR) genes, the
most important of which are mutations in the BRCA1,
BRCA2, and TP53 genes [5]. Sporadic cancer represents
approximately 85% of all cases of breast cancer and is as-
sociated with some of the risk factors mentioned above;
however, it has also been associated with exposure to car-
cinogens, such as air pollutants [6], electromagnetic radia-
tion [7], and DDR gene expression dysregulation [8].
According to their presentation, ductal carcinoma in situ
is the most diagnosed breast cancer type, followed by lobular
carcinoma in situ [9]. Breast cancer, in turn, is divided into
different subtypes based on the presence or absence of the
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estrogen receptor (ER), progesterone receptor (PR), and
HER2 receptor. .us, we can distinguish between a luminal
subtype, being ER/PR+, an Her2+ subtype, which has this
receptor overexpressed, and a triple negative or basal-like
subtype (TNBC). Following this classification, the luminal
subtypes can be divided into luminal A, characterized by
ER/PR+, HER2–, and low Ki67 expression, and luminal B,
characterized by ER/PR+, HER2+, and high Ki67 expression.
Subtype Her2+ is ER/PR negative, and the triple negative
indicates a lack of all these receptors [10–12].
Cell signal transduction is a fundamental process in the
development and progression of cancer. Hanahan and
Weinberg [13] noted that tumour cells exhibit a set of
characteristics or hallmarks, including uncontrolled prolif-
eration, genomic instability, and apoptosis evasion. To this
end, modifications to various cell signalling pathways pro-
mote tumour cell proliferation, progression, and survival
[14]. .ese alterations are due to mutations in oncogenes
that overexpress certain proteins, mutated proteins that
present uncontrolled activity, or inactivation of tumour
suppressor genes that favour these processes [15].
Many alterations in breast cancer cells that affect cell
signalling pathways have been described. In fact, variations
have been described in the responses mediated by calcium-
sensitive receptors [16, 17] or hypoxia-inducible factor [18]
or even in the apoptotic cell mechanisms themselves [19].
However, the alterations most studied and most directly
involved in the progression and development of breast
cancer pathways are those mediated by the ER and human
epidermal growth factor type-2 receptors (HER2/Neu or
c-ErbB2) [19]. .e activity of HER2 receptors in turn
promotes the signalling of other pathways such as the mi-
togen-activated protein kinases (MAPKs) or cell compo-
nents like glycogen synthase kinase-3 (GSK-3) and PI3K/
Akt/mTOR pathways, both represented in Figure 1,
denoting the importance of signal integration and trans-
duction processes in the progression and development of
breast cancer [20–23].
2. Importance of the PI3K/AKT/mTOR
Pathway in Cancer
PI3K/Akt/mTOR is a cell signalling pathway involved in
growth, proliferation, survival, motility, metabolism, and
immune response regulation [24, 25]. .is pathway has also
been associated with a great variety of diseases and syn-
dromes, such as tuberous sclerosis, Parkinson’s disease, and
vascular diseases [26–28].
Studies on PI3K/Akt/mTOR have also focused on cancer
research. Alterations to this pathway have been found in
practically all human tumours, including breast cancer,
where up to 60% of the tumours present different variations
that hyperactivate this pathway [29].
.e dysregulation of this pathway has been related to a
wide variety of cancer hallmarks, including uncontrolled
proliferation, genomic instability, and metabolic reprog-
ramming in tumour cells [13, 30]. In addition, PI3K/Akt/
mTOR pathway activation is one of the main causes of
cancer cell resistance to antitumour therapies [31]. .is
makes the PI3K/Akt/mTOR pathway a crucial object of
study for understanding the development and progression of
this disease, the role of this pathway as a potential thera-
peutic target, and the prognostic and diagnostic value of this
pathway in patients with breast cancer [32, 33].
3. PI3Ks in Tumours and Existing Therapies
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid
kinases that integrate signals from growth factors, cytokines,
and other extracellular stimuli and are related to the cell’s
response to these kinases [34]. .ree different classes of
PI3Ks are known, which in turn are divided into different
subclasses according to their affinity for certain substrates,
their sequence homology, and the functions that each of
these classes have in cell signal transduction; class I PI3Ks
are the most studied and the most clearly related to onco-
genic processes [35]. Class I PI3Ks are divided into the
following classes: PI3K IA, activated by receptor tyrosine
kinases (RTK) receptors, G-protein-coupled receptors
(GPCRs), and oncogenes such as Ras; and PI3K IB, regulated
exclusively by GPCRs [36]. Among these, class IA is the most
directly implicated in cancer. PI3K class IA consists of a
regulatory subunit, which can be p85α, p55α, p50α, p85β, or
p55c, and a catalytic subunit, which can be p110α, p110β, or
p110δ [37].
When a cellular receptor is activated, it dimerizes and
autophosphorylates in various regions, phosphorylating, in
turn, different adapter proteins and being recognized by the
p85 subunit, which binds to these phosphorylated residues
and generates a conformational change that releases p110,
the subunit that exerts catalytic activity. Consequently, a
phosphate group is added to phosphatidylinositol 4,5-
bisphosphate (PIP2), transforming it into phosphatidyli-
nositol (3,4,5)-trisphosphate (PIP3) [37]. Phosphatase and
tensin homolog (PTEN) phosphatase, which can remove a
phosphate from PIP3 to convert it into PIP2, is the most
important negative regulator of this pathway and one of the
tumour suppressors with the greatest effect on different
types of cancer [38]. PIP3 levels can also be regulated by
another tumour suppressor known as inositol poly-
phosphate-4-phosphatase type II B (INPP4B), which has the
same effect as PTEN. INPP4B loss has been considered a
marker of aggressiveness in TNBC tumours [39, 40].
Activating mutations in PIK3CA, the gene that encodes
the p110α catalytic subunit, have been identified as potent
oncogenic mechanisms implicated in the hyperactivation of
this pathway (Figure 2); these mutations are especially
noteworthy in breast cancer, where up to 27% of patients
have mutations in this gene [41]. Mutations in PI3KCA are
more common in luminal A subtype cancers, where they are
detected in 45% of tumours, followed by HER2+ mutations
with a frequency of 39%; luminal B represents 30% of
cancers, and TNBC alterations appear in 9% of cases [24].
.ese mutations affect mainly the helical domain of the
p110α subunit, reducing its repression by regulatory sub-
units or facilitating its interaction with IRS1 [42, 43]. PI3K
activation is a critical step in oncogenesis and plays a role in
treatment resistance in ER+/HER2+ breast cancers. .ere
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are currently PI3K inhibitors, which are being implemented
in clinical trials [44, 45].
Mutations in PTEN also result in important alterations
in cell signalling in patients with breast cancer. .e rela-
tionship between the loss of PTEN gene function and
unfavourable predictive factors has been observed in various
types of cancer, such as gastric, prostate, and colorectal
cancer [46–48]. Lu et al. [49] described how the activity
exerted by this phosphatase slows cell growth and induces
apoptosis and anoikis in breast cancer cells. .e results of a
meta-analysis of 27 studies and 10,231 cases performed by Li
et al. [50] showed that there seems to be an association
between PTEN expression loss and tumour aggressiveness in
breast cancer patients, especially those with ER, PR, and
TNBC tumours, thus demonstrating the involvement of
PTEN in the initiation and malignancy of breast cancer
tumour cells.
.ere are multiple PI3K inhibitors that have been de-
veloped or are in the study phase. .ese are classified
according to their specificity for each isoform and can be
divided into (1) first-generation inhibitors, also known as
pan-inhibitors of PI3K, which target all the different PI3K
class I isoforms (α, β, δ, or c), (2) second-generation in-
hibitors, which are specific to any of these isoforms, or (3)
dual PI3K/mTOR inhibitors. However, the efficacy shown
by these types of inhibitors as therapeutic agents is far from
that expected due to the coexistence of various mutations
present in tumour cells, compensatory feedback cycles, or
the toxicity associated with these treatments [24]. .at is
why research has focused on these inhibitors in combination
with other drugs, although much work remains.
Of the first-generation inhibitors, breast cancer studies
have focused on the use of pictilisib and buparlisib. .e role
of pictilisib as a pan-inhibitor (GDC-0941) in the inhibition
of the metastatic phenotype in thyroid carcinomas has been
demonstrated due to its action on PI3K and HIF-1α [51].
Zou et al. [52] observed the synergistic role that this drug
had with theMEK inhibitor UO126 in inhibiting NSCLC cell
growth. A study conducted by Schmid et al. [53] showed
how the combination of pictilisib with anastrozole obtained
a better response in inhibiting breast cancer cell prolifera-
tion. However, in a study conducted by Krop et al. [54], the
combined use of pictilisib with fulvestrant was not associated
with an improvement in the treatment of patients with
advanced-stage breast cancer resistant to endocrine therapy,
regardless of the presence or absence of PI3KCA mutations,
measured in terms of progression-free survival (PFS).
Buparlisib (BKM120), another pan-inhibitor of PI3K,
has demonstrated synergistic growth inhibitory effects in
combination with agents targeting the HER2 receptor in
preclinical studies [45]. Several early clinical trials have
shown positive results for the use of buparlisib in breast
cancer patients [55–57]. Another phase II clinical trial de-

























Figure 1: Overview of cell signalling mediated by the tyrosine kinase receptors (RTKs) Her2/Neu and estrogen receptors (ERs), two key
components of breast cancer development. .eir activation initiates the PI3K/Akt/mTOR and MAPK pathways, finally promoting cell
growth, proliferation, survival, and other hallmarks of cancer. Although this is a review of PI3K/Akt/mTOR signalling, it is important to
understand that the different pathways are connected by different points. In this figure, we have presented two examples: Ras, promoting
PI3K activation, and how some AGC kinases (such as SGK-3) activated by mTORC2 also interact with the MAPK pathway. Additionally,
GSK-3 plays an important role as well in the regulation of these pathways, represented in the figure. GSK-3 is an example of how complex
those interactions are, by the inhibition and activation of different molecules implicated in PI3K and MAPK pathways.
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buparlisib with trastuzumab and paclitaxel in women with
primary HER2+ tumours..e results showed little reliability
in its use; however, high rates of objective response and a
reduction in the Ki67 cell proliferation marker in the
ER+HER2+ subgroup denote the importance of future in-
vestigations of therapies targeting this pathway. Further-
more, two important clinical trials need to be mentioned
here: BELLE-2 and BELLE-3. Both were double-blind,
randomized, placebo-controlled phase 3 trials in which the
use of buparlisib was analysed in hormone receptor-positive
Her2-negative postmenopausal women. BELLE-2 aimed to
evaluate the combination of buparlisib plus fulvestrant
versus placebo and fulvestrant. .e results showed that the
use of this PI3K inhibitor combined with endocrine therapy
was associated with a significant improvement compared to
fulvestrant alone. However, this combination was also found
to have considerable toxicity, limiting its efficacy [59]. In
BELLE-3, 432 postmenopausal women who had previously
received endocrine therapy and mTOR inhibitors were di-
vided again into two groups: a group that received fulves-
trant and buparlisib and a control group that received only
fulvestrant. Patients with fulvestrant plus buparlisib had a
longer PFS than those who received fulvestrant alone, but
again, the toxicity of this combination restricts its use [60].
On the whole, these works highlight the importance of
performing further studies with PI3K-α-specific inhibitors
to provide the greatest benefits.
Currently, research is also aimed at the use of second-
generation PI3K inhibitors, such as alpelisib (BYL719) and
taselisib (GDC0032), which target the PI3K-α isoform, as a
higher-safety profile is expected compared to previous in-
hibitors [61]. Numerous previous studies seem to indicate
that mutations in PI3KCA in ER+ tumours decrease the
response rate of breast cancer tumours to antiestrogenic
therapy [62, 63]. A series of preclinical cell models developed
by Fritsch et al. [64] demonstrated how cells with mutations
in PIK3CA had greater sensitivity to alpelisib, while cell lines
without this mutation had selective sensitivity. A phase III
clinical trial showed how patients with advanced tumours
and mutations in PIK3CA benefited from the use of alpelisib
in combination with fulvestrant; compared with fulvestrant













Figure 2: Mechanism of action of PI3K and PTEN. RTK receptors are activated, phosphorylating themselves and other series of adapter
proteins, such as IRS-1. In this case, the regulatory subunit p85 binds to these residues and releases the catalytic subunit p110α, which adds a
phosphate to PIP2 and transforms it into PIP3, which will subsequently activate Akt. PTEN prevents this activation by dephosphorylating
PIP3. .e loss of function of this gene, represented in red, or activating PI3KCA mutations, shown in green, can overactivate this route,
favouring the development of cancer.
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response rates [65]. In fact, alpelisib has recently become the
first PI3K inhibitor approved by the FDA for the treatment
of breast cancer, so the study of this type of inhibitor is a
growing point of interest in actual research. Other pre-
clinical studies also reported the efficacy of taselisib in
cellular models with mutations in PIK3CA in breast cancer
[66]. SANDPIPER is an ongoing randomized, double-blind
phase III clinical trial with 631 postmenopausal women with
ER+HER2- PI3KCA mutations who showed progression or
recurrence during or after aromatase inhibitor (AI) therapy.
.is trial aims to investigate the efficacy and safety of
taselisib plus fulvestrant in comparison to a fulvestrant alone
control group (NCT02340221). SOLAR-1 is another on-
going phase III clinical study designed to evaluate the use of
alpelisib plus fulvestrant in ER/PR+Her2– advanced cancer
patients after treatment with AI (NCT02437318). Currently,
GDC-0077, another second-generation PI3K-α inhibitor, is
being tested in a phase I clinical trial in patients with
PIK3CA mutant solid tumours that are locally advanced or
metastatic, including breast cancer, and GDC-0077 is being
tested in combination with targeted therapies focused on the
ER/PR+Her2– subtype (NCT03006172).
Regarding third-generation inhibitors or dual PI3K/
mTOR inhibitors, the role of some of these inhibitors, such as
BEZ235, has been studied in combination with other in-
hibitors, such as everolimus (RAD-001), and these inhibitors
have been shown to exert a synergistic action by decreasing
the growth of some TNBC cell lines, such as MDA-MB-231
cells or the ER+MCF-7 line [67]. .e combination of BEZ-
235with autophagy inhibitors has also been studied, and these
combinations have resulted in inhibited proliferation and
increased apoptosis in breast cancer cells [68]. However,
clinical studies of BEZ-235 have not yielded promising
outcomes. A phase I/IB study of BEZ-235 in patients with
Her2+ advanced breast cancer showed that the safety profile
of this inhibitor was not adequate [69]. Nevertheless, clinical
studies of BEZ235 are ongoing in patients with metastatic
breast cancer [70]. Some previous studies indicate how AIs
can be combined with PI3K/mTOR inhibitors for treating
patients with resistance to endocrine therapy who present
with ER+HER-metastatic cells. In addition, it has been
studied how the PF-04691502 inhibitor is currently used for
combined treatment with tamoxifen for treating breast cancer
stem cells (BCSCs); in this manner, the resistance they pre-
sented when tamoxifen was applied in the absence of another
drug was avoided, and the importance of this pathway in
therapy resistance and in the formation of mammals was
shown [71]. Finally, another dual PI3K/mTOR inhibitor,
GDC-0980, has been shown to be particularly effective in
BRCA-competent TNBC when combined with a PARP in-
hibitor and carboplatin because it inhibits the DDR system
[72]. Studies on the efficacy of DDR inhibitors in breast cancer
therapy are discussed in previous reviews [73].
4. AKT in Tumours and Existing Therapies
RAC-alpha serine/threonine-protein kinase (Akt), also
known as protein kinase B (PKB), is a serine-threonine
kinase that has three different isoforms encoded by three
different genes: Akt1, Akt2, and Akt3. However, it is Akt1
that has beenmost associated with cancer [74]. Akt1 binds to
PIP3 via pleckstrin homology (PH) domains [75]. .is in-
teraction localizes Akt to the cell membrane, resulting in the
subsequent phosphorylation of the .r308 and Ser473
residues by 3-phosphoinositide-dependent protein kinase-1
and -2 (PDK1 and PDK2). While PDK1 is activated by PIP3,
PDK2 forms part of the mTORC2 complex [76].
.e effects of Akt activation include the activation of
MDM2, a p53 inhibitor, and the inhibition of other proteins
involved in stimulating cell survival in stress situations [77].
.e activation of Akt has also been associated with the
inhibition of p21 and p27, which are involved directly in cell
cycle control [78], and GSK-3β, as shown in Figure 3. GSK-
3β inactivation is directly related to cell metabolism
reprogramming and, more specifically, to the uptake and use
of glucose, which favours the Warburg effect [79]. However,
the role of GSK-3β in cancer remains controversial. Some
studies have reported that GSK-3βmay function as a tumour
promoter. GSK-3β knockdown cells were associated with
decreased levels of Bcl-2 and VEGF, thus suggesting the role
of GSK-3β in inhibiting apoptosis and promoting angio-
genesis [80]. On the other hand, previous findings have
indicated GSK-3β as a tumour suppressor in breast cancer
because it increases the sensitivity of chemotherapy and
inhibits PI3K/Akt and Wnt signalling, thus playing a key
role in the cell cycle and survival [81, 82]. .e interaction of
GSK-3 with PI3K/Akt pathway is represented in Figure 1.
.e activation of Akt is also related to the activation of
mTORC1. In addition, Akt is involved in the activation and
inactivation of various transcription factors; for example, it
binds 14-3-3 proteins and prevents the translocation of
FOXO to the nucleus [83]. Akt is also important in the
regulation of NF-κβ-dependent gene transcription and
CREB-1 overactivation, thus promoting the expression of
antiapoptotic genes such as Bcl-2 and mcl-1 [84, 85].
.e hyperactivation of Akt and consequently mTOR
may facilitate the resistance that some patients with breast
cancer have to endocrine therapies; in these patients, an
inverse correlation was established between Akt activation
and a partial treatment response [86, 87].
In breast cancer, the most frequent mutation is E17K-
Akt1, representing 2% of all breast cancers. .is mutation
increases the affinity of the PH domain for lipids, resulting in
the constitutive localization of Akt in the cell membrane
[88]. Currently, there are phase I and II clinical trials with
allosteric and catalytic Akt inhibitors. Hyman et al. [89]
proposed the use of the E17K-Akt1 mutation as a predictive
marker of the response to the catalytic inhibitor AZD5363,
with promising results. However, studies with the allosteric
inhibitor MK-2206 combined with hormone therapy re-
ported benefit ratios of only 42% [57].
In addition, recent studies indicate that there are other
proteins also activated by PI3K that contribute to the de-
velopment of cancer. Lien et al. [30] described that Akt is not
always hyperactivated in the presence of PI3KCA or PTEN
mutations; the authors also showed the role that other PI3K-
dependent proteins may play in the resistance to pathway
inhibitors and how these proteins can substitute for Akt-
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mediated signalling, indicating that further knowledge re-
garding these pathways is important for developing
promising future therapies (Figure 3).
5. mTOR in Tumours and Existing Therapies
.e mammalian target of rapamycin (mTOR) is a protein
kinase comprising two distinct complexes, mTORC1 and
mTORC2. Both complexes are associated with a set of
proteins that can be common or specific to each complex
[90]. mTORC1 is a complex formed by the mTOR, Raptor,
Deptor, Pras40, and mLST8 proteins [91]. .is complex is
activated by Akt via inhibition of the tuberous sclerosis
complex (TSC) [92]. In turn, TSC inhibits mTORC1 due to
its ability to inactivate RHEB, a GTPase that activates this
complex. mTORC1 responds to amino acids, stress, oxygen
levels, energy needs, and growth signals [24]. .e activation
of mTORC1 seems to be involved in multiple cellular
processes, including protein synthesis control, through
phosphorylation of the ribosomal proteins S6K1 and 4E-
BP1, the regulation of metabolism, and the inhibition of
autophagy [93].
mTORC2 is a complex that shares certain components
with mTORC1, such as mTOR kinase, mLST8, and Deptor.
In addition, it contains the Rictor protein and the subunits
Sin1 and Protor 1/2 [91]. .is complex is insensitive to
rapamycin, unlike the mTORC1 complex [94]. mTORC2 is
activated by growth signals and controls cell proliferation
and survival processes, as well as the cytoskeleton, mainly by
phosphorylating other proteins such as Akt, which, in turn,
is the main activator of mTORC1 [95]. In fact, mTORC2
phosphorylates AGC kinase family members, which are Akt,
SGK, and PKC (Figure 1), all of which have oncogenic effects
[96, 97]. .e role of SGKs is also interesting in cancer be-
cause they interact at various levels with MAPK signalling
and are related to the tumourigenesis process in PI3K
mutants through Akt-independent but SGK-3-dependent
malignant transformation (Figure 1) [98]. mTORC2 also
interacts with the retinoblastoma (Rb) tumour suppressor.
Previous studies have demonstrated that Rb may inhibit Akt
activation by inhibiting the mTORC2/PDK1 phosphoryla-
tion of Ser-473 Akt [99]. Furthermore, mTORC2 has been
associated with the control of the expression of glycolytic
genes by epigenetic regulation of H3K56Ac levels in glioma
cells [100], suggesting the different and important roles that
this complex may have in cancer progression and regulation.
Everolimus is one of the main drugs that targets mTOR,
and numerous studies have demonstrated its effectiveness in
breast cancer therapy [101]. Du et al. [102] reported the
efficacy of everolimus in the inhibition of antiapoptotic
proteins such as Bcl-2, as well as in breast cancer cell cycle
and growth arrest and in disease progression. Other studies
have shown the efficacy of everolimus in the treatment of
advanced ER+PR+ breast cancer [103]. Everolimus is an
allosteric inhibitor of mTORC1 but not mTORC2 and can
increase Akt phosphorylation by not binding the latter
inhibited complex. Dual inhibitors of mTOR, affecting both
complexes, have been studied. Leung et al. [104] demon-
strated in vitro the synergy that this drug presented with
other pathway inhibitors, such as dual mTOR inhibitors,
representing new strides for greater efficacy of the developed
































Figure 3: Activation of Akt after joining to PIP3 by its PH domain. PDK1 and PDK2, present in mTORC2, phosphorylate Akt, which will
activate and inhibit a series of genes, transcription factors, and proteins, represented in red, such as the TSC complex, which will eventually
activate mTORC1, resulting in a series of cellular responses. We have remarked in green the components which are stimulated or overactive
in these cells. .is figure also shows the main therapies developed to focus on this pathway.
6 Journal of Oncology
Among the dual inhibitors are AZD8055, AZD2014, and
MLN0128, which are in clinical development but have al-
ready demonstrated efficacy in numerous studies [105, 106].
.ese inhibitors show better results compared to mTORC1
inhibitors in blocking the PI3K/Akt/mTOR pathway as
measured by 4-EBP1, SK6, and p-Akt inhibition [107]. .e
effectiveness of these inhibitors has been demonstrated even
in everolimus resistance acquired by mutations in the
rapamycin binding domain of mTOR (Figure 3) [108]. Here,
it is important to discuss the role of mTOR inhibitors and
their relationship with the DNA-dependent protein kinase
catalytic subunit (DNA-PKcs), another key component of
the DDR system. Low levels of DNA-PKcs protein ex-
pression were related to higher tumour grade, dedifferen-
tiation and mitotic index, and poor survival [73, 109]. CC-
115, a dual inhibitor of mTOR and DNA-PKcs, has been
shown to inhibit cell growth in vitro by blocking DDR
pathways, thus inducing apoptosis in many cancer lines,
including breast cancer cells [110]. Currently, a phase I
clinical trial with CC-115 is ongoing. Other studies also
report the role of the DNA-PK inhibitor NU7441 in sen-
sitizing breast cancer cells to ionizing radiation and doxo-
rubicin [111].
Recently, an mTORC2-selective inhibitor based on
nanotechnology for HER2 amplification combined with the
HER2 inhibitor lapatinib was validated in TNBC, showing
its promising efficacy for both subtypes [112].
6. IRS4 in Tumours and the Relationship with
PI3K/Akt/mTOR in Breast Cancer
Insulin receptor substrates (IRSs) are a set of adaptive cy-
toplasmic proteins that were originally identified by their
role in insulin signalling [113]. .e IRS family comprises six
members. IRS1 and IRS2 are the best studied variants due to
their broad expression in different tissues, and they strongly
resemble each other in their structures [114]. IRS3 has been
found in rodents but not in humans [115]. IRS5/DOK4 and
IRS6/DOK5 are two distant members of the family with
greater resemblance to each other than to the other IRSs
[116]. .e present study will review IRS4, which has been
implicated in some types of cancer, such as breast cancer,
squamous carcinoma of the lung, sarcomas, and acute
lymphoblastic leukaemia [117, 118].
IRS phosphorylation occurs at tyrosine residues, gen-
erally through RTK-type receptors, thus inducing a sig-
nalling cascade that, in turn, promotes the activation of other
pathways such as PI3K/Akt or MAPK (Figure 1) [114, 119].
However, Ikink et al. [120] demonstrated that IRS4, unlike
other family members, did not require growth factors,
leading to the proliferation of mammary epithelial cells due
to elevated basal activation of the PI3K/Akt/mTOR pathway.
.is activation is achieved through the interaction of IRS4
with the p85 subunit [121]. In addition, an association was
found between adenovirus infection or certain retroviruses
and increased levels of IRS4 [121, 122].
Other studies have shown that there is a positive cor-
relation between IRS4 levels and other proteins involved in
breast cancer, such as Breast Tumor Kinase (Brk), a kinase
that is overexpressed in 80% of breast tumour cells, indi-
cating the importance of this protein in the development of
breast cancer [123, 124].
It has also been observed that IRS4 induces resistance to
trastuzumab and lapatinib, two treatments directed against
HER2+ breast cancer cells, because it is involved directly in
the hyperactivation of the PI3K/Akt/mTOR pathway, which
is ultimately responsible for this resistance, as shown in
previous studies; thus, IRS4 is a promising therapeutic target
for these types of tumours that are resistant to treatment
[125, 126].
7. Future Directions
.e study of cellular events that occur in oncogenic pro-
cesses is essential to understand the treatment actions we can
take. Furthermore, it is important to understand that car-
cinogenesis involves a wide range of changes in tumour cells
that enable their malignant transformation. From this
perspective, the PI3K/Akt/mTOR cell signalling pathway is
one of the key points of study that could result in im-
provements in the existing survival curves after good ana-
tomopathological studies and analyses of the efficacy and
efficiency of the inhibition. Despite the existence of selective
PI3K/Akt/mTOR inhibitors and current clinical trials, the
underlying cellular mechanisms are not yet known. Studying
the existing scientific literature helps to understand the
current state and the possible paths to be taken. Tomaximize
the efficacy of the inhibitors and decrease their toxicity,
PI3K/Akt/mTOR targeting is commonly combined with
additional treatments, such as endocrine therapy or DDR
inhibitors. Current challenges may be to minimize the side
effects of these therapies as well as to increase their speci-
ficity, thus bringing more benefits to the patients who need
to receive this type of treatment.
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